Xagenic Inc., a Toronto, Canada-based molecular diagnostics company developing a new technology for decentralized, rapid diagnostic testing and a true point-of-care platform. Our aim is to enable on-demand, near patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of first consultation. This will dramatically improve patient care and reduce health care costs. Xagenic has adapted this technology to permit rapid, enzyme-free detection of nucleic acids from clinical samples.
We are commercializing a simple and fully automated technology platform that will enable widespread decentralized diagnostic testing to be performed outside of clinical laboratories. Our team is developing infectious disease tests that will allow the detection of a variety of analytes in situations where rapid test turnaround will provide clinically actionable results.
Funding Rounds (3) - $35.5MUpdate
The OETF will co-invest — with qualified venture capital funds and other private investors —...
Capital Security and Venture Capital
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on...
BDC Capital was added to CrunchBase in 2013
QIAGEN N.V., through its subsidiaries, provides technologies and products for preanalytical...
MaRS is a non-profit organization that partners with entrepreneurs, researchers, business and...